Geron Corporation

NASDAQ:GERN

Biotechnology

Healthcare
$0.99 +4.07%

+$0.05 today

Market cap
$638.38M
Beta
0.60
P/E (TTM)
-12.3
EPS (TTM)
-$0.10
52W Low $1.04High $2.01

Volume 34.97M

Average 16.28M

GERN Other Non-current Liabilities

Long-term obligations not reported separately, such as lease or pension liabilities.

Geron CorporationNASDAQ: GERN

Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Other non-current liabilities remains negative

Q1 FY2026 other non-current liabilities was $0, compared with $110.38M a year earlier.

Context

  • Other non-current liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, down 19.6 pp from a year earlier.
  • Other non-current liabilities increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether other non-current liabilities keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
Year agoMar 2025
$110.38M-100.0% since
Other Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Other Non-current Liabilities vs competitors

How GERN compares with its peers on the latest reported figures

  • GERN's Mar 2026 other non-current liabilities of $0 is the 3rd highest of the 8 companies compared; the peer median is $0.
  • Its year-over-year change of -100.0% is the 3rd highest of 5, against a peer median of -72.4%.
  • Other non-current liabilities amounts to 0.0% of total assets for GERN, versus a peer median of 0.0%.
GERN Competitors Peer median
Other Non-current Liabilities for GERN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
INCYIncyte CorporationJun 2026$187.7M -44.8%-8.7%2.4%
DMRADamora Therapeutics, Inc.Mar 2026$27K -40.0%—0.0%
GERNGeron CorporationMar 2026$0 -100.0%—0.0%
COAGHemab Therapeutics Holdings, Inc. Common StockJun 2026$0 ——0.0%
SLSSELLAS Life Sciences Group, Inc.Sep 2026$0 ——0.0%
RIGLRigel Pharmaceuticals, Inc.Mar 2026$0 -100.0%—0.0%
IPSCCentury Therapeutics, Inc.Mar 2026$0 -100.0%—0.0%
ATNMActinium Pharmaceuticals, Inc.Jun 2026$0 ——0.0%
Peer median (excluding GERN) $0-72.4%-8.7%0.0%

Competitors are the stored peer set for GERN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents34.87M56.85M70.02M79.02M79.44M
Short-term Investments148.85M115.9M263.68M327.55M280.36M
Net Receivables1.76M3.14M1.66M38.8M39.23M
Inventory00038.71M0
Other Current Assets364K4.36M5.99M6.91M121.25M
Total Current Assets187.21M180.25M341.35M490.99M520.27M
Property, Plant & Equipment (Net)5.38M4.94M4.73M4.19M884K
Goodwill00000
Intangible Assets00000
Long-term Investments28.65M043.3M94.52M41.29M
Tax Assets00000
Other Non-current Assets4.8M5.39M4.7M4.08M8.1M
Total Non-current Assets38.83M10.33M52.73M102.79M50.27M
Total Assets226.03M190.58M394.08M593.78M570.54M
Account Payables6.69M10.19M6.16M8.6M11.26M
Short-term Debt020.95M46.89M018.45M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities8.1M11.53M13.76M43.18M80.84M
Total Current Liabilities45.52M76.69M108.07M88.3M111.54M
Long-term Debt49.83M30.21M35.05M118.48M231.68M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities000104.42M0
Total Non-current Liabilities54.1M33.88M38.06M225.16M233.13M
Total Liabilities99.62M110.58M146.13M313.46M344.67M
Common Stock324K390K545K606K640K
Retained Earnings(1.27B)(1.41B)(1.6B)(1.77B)(1.86B)
Accumulated OCI(173K)(219K)185K261K269K
Other Stockholders Equity00000
Minority Interest00000
Total Equity126.42M80M247.95M280.32M225.87M
Total Debt55M55.75M85.9M121.72M251.57M
Net Debt20.13M(1.09M)15.88M42.7M172.13M

Geron Corporation

NASDAQ:GERN

Intrinsic Alpha fair value

Locked

Current Price

$0.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.